Halozyme Therapeutics, Inc. (HALO)
69.34
+0.62
(+0.90%)
USD |
NASDAQ |
May 27, 14:01
Halozyme Therapeutics Free Cash Flow : 667.65M for March 31, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.710B |
| Agenus, Inc. | -87.53M |
| Inovio Pharmaceuticals, Inc. | -83.57M |
| Curis, Inc. | -28.95M |
| Plus Therapeutics, Inc. | -21.72M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 180.08M |
| Cash from Investing (Quarterly) | -2.877M |
| Cash from Financing (Quarterly) | -1.613M |
| Free Cash Flow Per Share (Quarterly) | 1.435 |
| Free Cash Flow to Equity (Quarterly) | 208.90M |
| Free Cash Flow to Firm (Quarterly) | 180.92M |
| Free Cash Flow Yield | 7.91% |